RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Boston, MA · Burlington, MA · +172 more sites